C-Reactive Protein Causes Insulin Resistance in Mice Through Fcγ Receptor IIB–Mediated Inhibition of Skeletal Muscle Glucose Delivery

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
C-Reactive Protein Causes Insulin Resistance in Mice Through Fcγ Receptor IIB–Mediated Inhibition of Skeletal Muscle Glucose Delivery

Keiji Tanigaki,1 Wanpen Vongpatanasin,2 Jose A. Barrera,1 Dmitriy N. Atochin,3 Paul L. Huang,3 Ezio Bonvini,4 Philip W. Shaul,1 and Chieko Mineo1

Elevations in C-reactive protein (CRP) are associated with an increased risk of insulin resistance. Whether CRP plays a causal role is unknown. Here we show that CRP transgenic mice and wild-type mice administered recombinant CRP are insulin resistant. Mice lacking the inhibitory Fcγ receptor IIB (FcγRIIB) are protected from CRP-induced insulin resistance, and immunohistochemistry reveals that FcγRIIB is expressed in skeletal muscle microvascular endothelium and is absent in skeletal muscle myocytes, adipocytes, and hepatocytes. The primary mechanism in glucose homeostasis disrupted by CRP is skeletal muscle glucose delivery, and CRP attenuates insulin-induced skeletal muscle blood flow. CRP does not impair skeletal muscle glucose delivery in FcγRIIB−/− mice or in endothelial nitric oxide synthase knock-in mice with phosphomimetic modification of Ser1176, which is normally phosphorylated by insulin signaling to stimulate nitric oxide–mediated skeletal muscle blood flow and glucose delivery and is dephosphorylated by CRP/FcγRIIB. Thus, CRP causes insulin resistance in mice through FcγRIIB–mediated inhibition of skeletal muscle glucose delivery.


Numerous clinical studies indicate that chronic, mild increases in circulating levels of the acute-phase reactant C-reactive protein (CRP) are associated with insulin resistance (1–5). For example, in middle-aged men, independent of numerous risk factors including baseline BMI, individuals in the top quintile of CRP (>4.18 μg/mL) had a more than threefold greater risk of developing diabetes than those in the lowest quintile (<0.66 μg/mL) (6). However, the relationship between CRP and type 2 diabetes has been greatly debated (7–10), and whether CRP plays a pathogenic role is unknown.

In the current study, we determined how CRP influences glucose homeostasis in vivo, testing the hypothesis that CRP induces insulin resistance in mice. Additional studies were performed to address the following questions:

- Which regulatory processes in glucose homeostasis are altered by CRP?
- Is the effect of CRP on glucose homeostasis mediated by Fcγ receptors (FcγR) for IgG, which bind CRP to invoke its cellular actions in certain paradigms (11,12)?
- How does CRP action via FcγR cause insulin resistance?

RESEARCH DESIGN AND METHODS

Animal model. Experiments were performed in male wild-type and CRP-transgenic mice (TG-CRP) on CF-1 or C57BL/6 background (13–16), in endothelial nitric oxide synthase (eNOS-S1176D) mice (17,18), and in FcγRIIB−/−, FcγRIIB+/−, TG-CRP, FcγRIIB−/−, and FcγRIIB−/−;TG-CRP littermates (C57BL/6 background) (19). The transgene in the TG-CRP mouse consists of the protein-coding region of the CRP gene linked to the promoter/regulatory region of phosphoenolpyruvate carboxykinase (PEPCK). Although CRP expression can be enhanced by providing these mice a carbohydrate-free diet, such a diet is not necessary for the transgene to be expressed, and the mice fed normal chow display elevated CRP levels (13–16). After weaning, all mice were fed normal chow (Taklad Global 18% Protein Rodent Diet 2018). In select studies, enzyme-linked immunosorbent assays (ELISAs) were used to measure plasma CRP levels (13,14), and levels of tumor necrosis factor-α (TNF-α), adiponectin, and leptin (B&D Systems or Millipore). The care and use of all study animals was approved by the University of Texas Southwestern Institutional Animal Care and Use Committee and conducted in accordance with Public Health Service Policy on the Humane Care and Use of Laboratory Animals.

Glucose (GTT) and insulin tolerance tests (ITT). Mice were fasted for 4–6 h and injected intraperitoneally with g-glucose (1 g/kg body weight) for GTT or with insulin (1 units/kg body weight) for ITT. Tail vein blood samples were obtained at the indicated times for plasma glucose measurement by glucose meter (ONE TOUCH Ultra2, Johnson & Johnson). Plasma insulin concentrations were determined by ELISA (Crystal Chem Inc.).

Glucose infusion rate (GIR). After a 5-h fast, euglycemic-hyperinsulinemic clamps were performed with an insulin infusion at 20 mU/kg/min for 180 min. Euglycemia (1.20 ± 0.10 g/L) was maintained by measuring blood glucose every 10 min and adjusting a variable infusion of glucose. GIR was calculated as the mean of the values administered in 10-min intervals during the 180-min infusion period (20,21).

Administration of CRP. Mice were intraperitoneally injected with human recombinant CRP (200 μg, Calbiochem) or an equal volume of saline on days 11 and 14. Plasma glucose and insulin levels were determined at baseline and 2, 4, 6, and 8 h after injection. Plasma samples were analyzed by ELISA using recombinant CRP as standard.

In vivo and ex vivo glucose uptake. In vivo glucose uptake was measured as previously reported (22). Briefly, fasted mice were injected intraperitoneally with 2-deoxy-[14C]glucose ([14C]2-DG, Amersham; 2 μCi/g body weight) mixed with dextrose (20%) and labeled blood glucose was measured at 0–90 min. The plasma was deproteinized with ice-cold perchloric acid (3.5%), the supernatant was neutralized with 2.2 mol/L KHCO3, and radioactivity was determined in a liquid scintillation counter. The glucose-specific activity (degenerations/min/μmol) was calculated by dividing the radioactivity by the glucose concentration, and the area under the curve (AUC) was integrated for the duration of the experiment (90 min). Skeletal muscle (soleus and gastrocnemius) and liver were isolated, minced, and homogenized.
perigonadal white adipose tissue were harvested at 90 min. Peak plasma insulin concentrations during the in vivo glucose uptake experiments were 0.25 ± 0.03 nmol/L and 0.35 ± 0.04 nmol/L for wild-type and TG-CRP mice, respectively (13-week-old males, n = 6; P = 0.04).

To measure blood flow, 5 mmol/L D-2-[3H]-2-deoxy-[3H]-2-DG (66 Ci/mmol, New England Nuclear, Boston, MA) was injected intravenously in the presence of 0.2 mmol/L sodium azide. Blood flow was measured by the continuous monitoring of radioactivity in aortic blood sampled during the clamp were 0.14 ± 0.05 and 0.15 ± 0.04 nmol/L for wild-type and TG-CRP mice, respectively (n = 4–6; P = 0.05 and 0.04 nmol/L for wild-type and TG-CRP mice, respectively). The GIR was measured during a euglycemic–hyperinsulinemic clamp and was decreased 0.6 ± 0.46 and 0.93 ± 0.54 units per minute (n = 4–6; P = 0.05 and 0.04 nmol/L for wild-type and TG-CRP mice, respectively).

**Results**

**CRP induces insulin resistance in mice.** We first studied glucose and insulin homeostasis in 14–16-week-old male wild-type controls and TG-CRP mice. Compared with controls, fasting glucose and insulin levels were elevated in TG-CRP mice (Fig. 1A and B). TG-CRP mice also displayed abnormal GTT (Fig. 1C) and ITT (Fig. 1D). Plasma CRP levels were undetectable (<1 μg/mL) in controls and were 3–14 μg/mL in TG-CRP mice. Abnormal GTT and ITT were observed across the range of CRP levels studied (data not shown). The GIR was measured during a euglycemic–hyperinsulinemic clamp and was decreased >50% in TG-CRP versus control mice (Fig. 1E). Thus, TG-CRP mice with modest increases in CRP at levels known to be associated with the development of type 2 diabetes in humans (1–4,6) have insulin resistance.

We next investigated the age at which TG-CRP mice display abnormal glucose and insulin homeostasis and evaluated the effect of CRP on body weight and composition. Both 5- and 13-week-old male TG-CRP mice displayed fasting hyperglycemia and hyperinsulinemia (Fig. 2A and B). At 5 weeks, TG-CRP mice had body weights below those of wild-type mice and had a lower percentage of fat mass (Fig. 2C–E). At 13 weeks, TG-CRP and wild-type mice had similar body weights, but TG-CRP mice had a greater percentage of fat mass. Therefore, TG-CRP mice develop abnormal glucose and insulin homeostasis before an increase in fat mass. Studies in metabolic chambers revealed that TG-CRP mice did not have alterations in oxygen consumption, CO2 production, respiratory exchange rate, heat production, or food intake compared with wild-type mice (Supplementary Fig. 1A–E).

Plasma adiponectin levels were 5.8 ± 0.54 and 9.31 ± 0.94 μg/mL (n = 5/group), and leptin levels were 11.35 ± 1.20 and 14.43 ± 2.86 ng/mL (n = 5/group) in wild-type and TG-CRP mice, respectively, indicating that they are not altered by CRP in vivo. Plasma levels of TNF-α were undetectable in controls and in TG-CRP mice. There were also no differences in mRNA abundance for TNF-α or IL-6.
or for the macrophage markers F4/80 and Mac-2 in adipose tissue isolated from wild-type versus TG-CRP mice (data not shown). Thus, CRP alone does not cause systemic inflammation or promote inflammation in adipose tissue.

We next determined if the administration of CRP alters glucose and insulin homeostasis in wild-type male mice given recombinant human CRP or vehicle by intraperitoneal injection every other day for 14 days. Whereas vehicle-treated mice showed no changes, CRP-treated mice displayed fasting hyperglycemia and hyperinsulinemia on day 15 of the study (Fig. 3A and B). Shorter duration of CRP treatment (7 or 11 days) did not alter fasting glucose or insulin (data not shown). Body weight and fat and lean body mass were not affected by CRP treatment (Fig. 3C–E).

These results provide further evidence that CRP causes insulin resistance in vivo and that it does so independently of changes in body composition.

**FcγRIIB mediates CRP-induced insulin resistance.**

The FcγRs are IgG receptors that invoke the cellular actions of CRP in certain paradigms (11,12). To begin to determine how CRP causes insulin resistance, we tested the potential role of the inhibitory FcγR isoform designated FcγRIIB (29) in studies of FcγRIIB+/+, TG-CRP, FcγRIIB−/−, TG-CRP, FcγRIIB+/+, and FcγRIIB−/− littermates. Fasting glucose and insulin levels were elevated in FcγRIIB+/+; TG-CRP versus controls (FcγRIIB+/+) but were normal in FcγRIIB−/−; TG-CRP mice (Fig. 4A and B). Furthermore, GTT and ITT revealed that whereas FcγRIIB+/+, TG-CRP
have glucose intolerance and decreased insulin sensitivity, FcγRIIB<sup>−/−</sup>;TG-CRP have normal glucose tolerance and normal insulin sensitivity (Fig. 4C and D). Thus, FcγRIIB is required for CRP-induced insulin resistance.

We next evaluated FcγRIIB protein distribution in tissues from FcγRIII<sup>−/−</sup> mice with a chimeric antibody that recognizes both mouse FcγRIIB and FcγRIII. Microvascular endothelium in heart, brain, liver, and kidney displayed signal for FcγRIIB (data not shown). Importantly, positive microvascular endothelial cell staining was abundant in skeletal muscle (gastrocnemius) (Fig. 4E). Staining was negative with control unrelated IgG or with ch2.4G N297Q antibody applied to tissues from FcγRIIB<sup>−/−</sup> mice (Supplementary Fig. 2). In skeletal muscle there was colocalization of the receptor with the endothelial cell marker platelet endothelial cell adhesion molecule-1 (Fig. 4F), whereas it was not detected in myocytes (Fig. 4E and F, Supplementary Fig. 2), adipocytes, or hepatocytes (data not shown). Thus, the microvascular endothelium in the skeletal muscle is the well-recognized insulin target cell in which FcγRIIB is expressed.

**FIG. 2.** TG-CRP mice develop insulin resistance at an early age. Fasting plasma levels of glucose (A) and insulin (B), body weight (C), fat mass (D), and lean body mass (E) were measured in wild-type (WT) and TG-CRP mice at the age of 5 or 13 weeks. Values are mean ± SEM, n = 6. *P < 0.05 vs. wild-type.

CRP blunts skeletal muscle glucose delivery. To delineate the basis for the adverse effects of CRP on glucose and insulin homeostasis, we evaluated numerous processes. Wild-type and TG-CRP mice both had elevations in plasma insulin in response to glucose (Fig. 5A), indicating comparable capacity for pancreatic insulin secretion. This finding is consistent with a lack of FcγRIIB mRNA expression in pancreatic islets (data not shown). We also measured hepatic glucose production and found that CRP did not alter basal production or the fall in production in response to insulin (Fig. 5B).

We next determined if CRP affects tissue glucose delivery in studies of [³H]-2-DOG uptake in perigonadal white adipose tissue and gastrocnemius and soleus in male mice aged 10–13 weeks. Glucose uptake in white adipose was comparable in control and TG-CRP mice (Fig. 5C). Consistent with this finding, CRP did not alter glucose uptake in differentiated adipocytes in culture (Supplementary Fig. 3). In contrast, TG-CRP mice displayed 39% less skeletal muscle glucose uptake than wild-type mice (Fig. 5D). The selective impact of CRP on
skeletal muscle and not adipose glucose delivery was also apparent at age 5–6 weeks (Fig. 5E and F). Having discovered an abundance of FcγRIIB in skeletal muscle microvascular endothelium (Fig. 4E and F; Supplementary Fig. 2), in which insulin activates eNOS (30,31) to increase blood flow and microvascular recruitment and thereby promote glucose disposal (32–35), we next studied insulin-induced skeletal muscle blood flow in the hind limb. Basal blood flow was similar in control and TG-CRP mice (0.339 ± 0.152 and 0.234 ± 0.08 cm/s, respectively, n = 5; P = NS). However, whereas insulin infusion increased muscle blood flow by 60% in control mice (Fig. 5G), there was a complete lack of response in TG-CRP mice. To then confirm these findings by another means, we studied the effect of CRP treatment in wild-type mice. Because FcγRIIB, which is required for CRP-induced insulin resistance (Fig. 4A–D), is not expressed in skeletal muscle myocytes (Fig. 4E and F), the decrease in muscle glucose delivery caused by CRP is unlikely to be due to direct actions on insulin signaling in myocytes. This conclusion was strengthened in ex vivo studies of insulin-induced glucose transport in soleus and extensor digitorum longus muscles (Fig. 6A and B), which revealed similar insulin responses in muscles from wild-type and TG-CRP mice. To further determine whether the primary impact of CRP on glucose homeostasis occurs through actions on endothelium, changes in in vivo glucose uptake in response to CRP treatment were compared in wild-type versus eNOS-S1176D knock-in mice expressing a phosphomimetic form of eNOS (18). Insulin signaling in endothelial cells normally stimulates the phosphorylation of eNOS-S1176 (murine isoform, S1177 in human, this is associated with an impaired response of the skeletal muscle vasculature to insulin.

**FcγRIIB and eNOS antagonism mediate CRP impairment of muscle glucose delivery.** Because FcγRIIB, which is required for CRP-induced insulin resistance (Fig. 4A–D), is not expressed in skeletal muscle myocytes (Fig. 4E and F), the decrease in muscle glucose delivery caused by CRP is unlikely to be due to direct actions on insulin signaling in myocytes. This conclusion was strengthened in ex vivo studies of insulin-induced glucose transport in soleus and extensor digitorum longus muscles (Fig. 6A and B), which revealed similar insulin responses in muscles from wild-type and TG-CRP mice. To further determine whether the primary impact of CRP on glucose homeostasis occurs through actions on endothelium, changes in in vivo glucose uptake in response to CRP treatment were compared in wild-type versus eNOS-S1176D knock-in mice expressing a phosphomimetic form of eNOS (18). Insulin signaling in endothelial cells normally stimulates the phosphorylation of eNOS-S1176 (murine isoform, S1177 in human,
FIG. 4. CRP-induced insulin resistance is mediated by FcγRIIB, which is expressed in skeletal muscle microvascular endothelium. Fasting glucose (A) and insulin (B) levels were measured in FcγRIIB+/+, FcγRIIB−/−;TG-CRP, FcγRIIB−/−, and FcγRIIB−/−;TG-CRP littermates. Values are mean ± SEM, n = 4–8. *P < 0.05 vs. FcγRIIB+/+. †P < 0.05 vs. FcγRIIB+/−;TG-CRP. Glucose tolerance tests (C) and insulin tolerance tests (D) were performed in the same groups. Values are mean ± SEM, n = 4–8. *P < 0.05 vs. FcγRIIB+/+ at the indicated times. E: Expression of FcγRIIB in skeletal muscle. Immunostaining for FcγRIIB was performed on gastrocnemius from FcγRIIB−/− mice with chimeric antibody to mouse FcγRIIB and FcγRIII (ch2.4G2, N297Q). Positive signal for FcγRIIB was detected in the microvascular endothelium (arrows) and was absent in skeletal muscle myocytes. Scale bars = 50 μm. F: FcγRIIB expression in skeletal muscle was assessed by immunofluorescence in tissue from FcγRIIB+/+ vs. FcγRIIB−/− mice. The skeletal muscle sections were probed with anti-FcγRII (green) and anti-platelet endothelial cell adhesion molecule-1 (PECAM-1; red) antibodies. Merged images are also shown. Scale bars = 50 μm. (A high-quality digital representation of this figure is available in the online issue.)
FIG. 5. CRP decreases skeletal muscle glucose delivery and insulin-induced skeletal muscle blood flow and does not alter pancreatic insulin secretion or hepatic glucose production. A: Pancreatic insulin secretion was evaluated in 10–13-week-old wild-type (WT) and TG-CRP mice. After an intraperitoneal injection of D-glucose, plasma insulin levels were measured at the indicated times. Values are mean ± SEM, n = 8. *P < 0.05 vs. wild-type at the indicated time, †P < 0.05 vs. time 0. B: Hepatic glucose production was measured at baseline and during a hyperinsulinemic-euglycemic clamp.
CRP INDUCES INSULIN RESISTANCE VIA FC\textsubscript{Y}-RIIB

S1179 in bovine) (30,34) to activate the enzyme and increase muscle blood flow and microvascular recruitment and thereby promote glucose disposal (33–35). In prior work we showed that the CRP/Fc\textsubscript{Y}-RIIB tandem inhibits eNOS activation by causing eNOS-S1176 dephosphorylation (36,37). Therefore, the phosphomimetic eNOS in eNOS-S1176D mice is resistant to CRP antagonism (18,36,37). CRP did not alter glucose uptake in white adipose tissue of wild-type or eNOS-S1176D mice (Fig. 6C). However, whereas CRP blunted glucose uptake in the skeletal muscle of wild-type mice, as previously observed (Fig. 5D), uptake was unaffected by CRP in eNOS-S1176D mice (Fig. 6D).

Now knowing that eNOS antagonism by CRP underlies the impairment in muscle glucose disposal, and knowing that Fc\textsubscript{Y}-RIIB mediates CRP inhibition of eNOS (36,37), it would be predicted that Fc\textsubscript{Y}-RIIB is required for CRP to blunt muscle glucose delivery. Additional glucose uptake experiments were therefore performed in Fc\textsubscript{Y}-RIIB\textsuperscript{−/−};TG-CRP, Fc\textsubscript{Y}-RIIB\textsuperscript{−/−};TG-CRP, Fc\textsubscript{Y}-RIIB\textsuperscript{−/−}, and Fc\textsubscript{Y}-RIIB\textsuperscript{−/−} littermates. Glucose uptake in white adipose tissue was comparable in the four groups (Fig. 6E), and as expected, muscle glucose uptake was impaired in Fc\textsubscript{Y}-RIIB\textsuperscript{−/−};TG-CRP versus Fc\textsubscript{Y}-RIIB\textsuperscript{−/−} mice (Fig. 6P). In contrast, muscle glucose uptake was not adversely affected by CRP in Fc\textsubscript{Y}-RIIB\textsuperscript{−/−};TG-CRP mice. These cumulative findings indicate that CRP impairs skeletal muscle glucose delivery, that this is caused by CRP attenuation of the endothelial actions of insulin in skeletal muscle, and that Fc\textsubscript{Y}-RIIB in the muscle microvasculature mediates this process.

**DISCUSSION**

Numerous studies have indicated that chronic, modest elevations in CRP are associated with the development of insulin resistance in humans (1–6). However, there has been debate whether these associations are independent of the relative degree of adiposity of the individual or an epiphenomenon of obesity (7–10). Furthermore, it has been unknown whether CRP is a pathogenetic factor in insulin resistance. We therefore investigated the direct effects of CRP on insulin sensitivity in mice and discovered, using multiple strategies, that modest elevations in CRP cause insulin resistance. These findings reveal an entirely new modifier of glucose homeostasis. When combined with our prior observations that CRP causes hypertension and impairs endothelial repair (13,14), these findings also indicate that CRP may be a common etiologic factor in the cardiovascular and metabolic disorders that often complicate chronic inflammatory conditions.

In the current study, CRP-induced insulin resistance was related to impaired skeletal muscle glucose delivery. This mechanism may also underlie the trend toward insulin resistance observed in TG-CRP mice fed normal chow in a recent report that did not interrogate how CRP affects insulin action (38). We reveal a mechanistic link between the attenuated skeletal muscle glucose delivery and the systemic insulin resistance caused by CRP because both were normalized in Fc\textsubscript{Y}-RIIB\textsuperscript{−/−} mice. Importantly, pancreatic insulin production, hepatic glucose production and insulin sensitivity, and adipose glucose uptake were unaffected by CRP. Consistent with these observations, we found that Fc\textsubscript{Y}-RIIB is expressed in the skeletal muscle microvasculature but not in skeletal muscle myocytes, pancreatic islets, hepatocytes, or adipocytes. Also consistent with a key role for altered skeletal muscle vascular function and not altered myocyte function in CRP-induced insulin resistance, we found that CRP does not inhibit insulin-induced glucose uptake in isolated skeletal muscles studied ex vivo. Moreover, the primary defect of impaired skeletal muscle glucose delivery was fully prevented in the eNOS-S1176D mice expressing a phosphomimetic eNOS protected from CRP antagonism. From these multiple findings we conclude that CRP-induced insulin resistance is primarily due to impaired glucose delivery to skeletal muscle caused by Fc\textsubscript{Y}-RIIB-mediated inhibition of endothelial insulin action.

Our current findings are consistent with the recognized interrelationship between NO, insulin action in endothelium, and metabolic homeostasis. The major aspects of the metabolic phenotype of the TG-CRP mice mirror observations in eNOS\textsuperscript{−/−} mice. The latter have a decreased GIR during euglycemic-hyperinsulinemic clamping, blunted insulin-induced skeletal muscle blood flow, and skeletal muscle glucose delivery that is decreased by 40% compared with wild-type mice, whereas the response to insulin in ex vivo studies of skeletal muscle glucose uptake is normal (39). Furthermore, the attenuated skeletal muscle glucose uptake and consequences on global insulin sensitivity that we observe with CRP elevation are in close agreement with a recent report in which insulin receptor substrate 1 and 2 were both deleted from endothelium in a cell-specific manner (40). This phenocopying strengthens the evidence that the insulin resistance caused by CRP is most likely primarily due to adverse effects on insulin action in endothelium.

In addition to displaying insulin resistance, we discovered that older TG-CRP mice (13 weeks old) have increased fat mass. An increase in fat mass can contribute to the development of insulin resistance (41,42). However, this is not a primary mechanism in the current study because TG-CRP mice develop hyperglycemia and hyperinsulinemia as early as age 5 weeks, when fat mass is not increased, and the exogenous administration of recombinant CRP for 2 weeks causes hyperglycemia and hyperinsulinemia without affecting body composition. Mice with muscle-specific inactivation of the insulin receptor have increased fat mass (43), and the authors have speculated that this is due to the increase in glucose transport to adipose tissue also found in these mice (43). In TG-CRP mice, glucose uptake in adipose tissue is not altered. The basis for the increased adiposity found in older TG-CRP mice is yet to be elucidated.

clamp (insulin – or +) in 10–13-week-old WT or TG-CRP mice with insulin infusion at 4 mU/kg/min. Values are mean ± SEM, n = 14–15. *P < 0.05 vs. no insulin. In vivo glucose uptake was evaluated in WT or TG-CRP mice at age 10–13 weeks (C and D), or at age 5–6 weeks (E and F). Mice were injected intraperitoneally with [\textsuperscript{3}H]-2-DG, and the specific accumulation of [\textsuperscript{3}H]-2-DG-6-phosphate in white adipose tissue (WAT) isolated from the perigonadal fat pad (C and E) and soleus and gastrocnemius (Sol + Gas) skeletal muscle (D and F) was determined. Values are mean ± SEM, n = 5–6. *P < 0.05 vs. WT. G: Skeletal muscle blood flow was measured in 10–14-week-old WT or TG-CRP mice during a hyperinsulinemic-euglycemic clamp with insulin infusion at 20 mU/kg/min. Values are mean ± SEM, n = 6. *P < 0.05 vs. 0 h. †P < 0.05 vs. WT at the indicated times. H and I: Effect of exogenous CRP on in vivo glucose uptake. WT mice were injected with vehicle or CRP 2 h before intraperitoneal injection of [\textsuperscript{3}H]-2-DG, and the specific accumulation of [\textsuperscript{3}H]-2-DG-6-phosphate in white adipose tissue (WAT) isolated from perigonadal fat pad (H) and soleus and gastrocnemius (Sol + Gas) skeletal muscle (I) was determined. Values are mean ± SEM, n = 6. *P < 0.05 vs. vehicle.
Now knowing that CRP causes abnormal glucose homeostasis in mice and that FcγRIIB is critically involved, the role of CRP in insulin resistance in humans can be more effectively interrogated. Studies in lupus patients indicate that genetic variations in human FcγRIIB are common and that they impact receptor function (44), and there is also great variability in Fc receptor gene copy number (45). As such, there may be genetic modifiers of CRP action in humans, and previous studies that attempted to link CRP levels directly to phenotypes such as insulin resistance may have been oversimplified. Genetic variations in FcγRIIB can now be investigated to better understand how CRP contributes to the pathogenesis of insulin resistance in humans.
In summary, we have demonstrated that modest elevations in CRP cause insulin resistance in mice by decreasing skeletal muscle glucose delivery and that the process is due to attenuated endothelial insulin action mediated by FcγRIIB, which is abundant in skeletal muscle microvascular endothelium. By targeting the common underlying mechanism, namely endothelial dysfunction caused by the CRP-FcγRIIB tandem, future therapies aimed at CRP or its receptor may normalize the hyperinsulinemia and insulin resistance that often accompany chronic inflammatory conditions.

ACKNOWLEDGMENTS
This work was supported by the American Diabetes Association Grant 1-10-BS-124 (C.M.), National Institutes of Health Grants HL-75473 (P.W.S.) and NS-33335 (P.L.H.), the Donald W. Reynolds Cardiovascular Clinical Research Center (W.V.), the O’Brien Kidney Center (W.V.), the American Heart Association Scientist Development Grant 0835344N (D.N.A.), and the Children’s Medical Center of Dallas Research Foundation (P.W.S.).

P.W.S. reports having received honoraria for participation in scientific meetings at which data in this article were discussed. E.B. is an employee of MacroGenics, Inc., a company involved in the development of therapeutics antibodies and whose ch2.4G N297Q antibody was used in this study. No other potential conflicts of interest relevant to this article were reported.

K.T. and C.M. conceived the study, did experimental work, and wrote the manuscript. W.V. performed experimental work and assisted in data analysis and interpretation. J.A.B. performed quantitative RT-PCR analyses. D.N.A. and P.L.H. created the eNOS knock-in mice used in the study and assisted in data interpretation. E.B. contributed the monoclonal FcγRIIB antibodies, aided in the design of studies using the antibodies, and was involved in manuscript preparation. P.W.S. was involved in study conception, project planning, financing, supervision, data analysis, and manuscript preparation. C.M. and P.W.S. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Parts of this study were presented at the Annual Scientific Sessions of the American Heart Association, Orlando, Florida, 14–18 November 2009.

The authors thank Christopher Longoria (University of Texas [UT] Southwestern Medical Center) and Mohamed Ahmed (UT Southwestern Medical Center) for technical assistance, Dr. Daniela Rogoff (UT Southwestern Medical Center) for her help in glucose uptake experiments, Dr. Jen-Chieh Chuang (UT Southwestern Medical Center) for pancreatic islet experiments, Dr. David Inuenza (Macrogenics, Inc) and Junko Umetani (UT Southwestern Medical Center) for immunohistochemical analysis, and Dr. Amira Klip (The Hospital for Sick Children, Toronto, Ontario, Canada) for providing them with L6/GLUT4myc cells. The authors also thank Drs. Philipp Scherer, Joyce Repa, Deborah Clegg, and Eric Berglund (all at UT Southwestern Medical Center) for their helpful discussion.

REFERENCES
5. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:1027–1034
8. Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have all the answers? Am J Med 2007;120(Suppl. 1):S10–S16; discussion S16–S17
16. Xia D, Samols D. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc Natl Acad Sci USA 1997;94:2375–2380
35. Richards OC, Raines SM, Attie AD. The role of blood vessels, endothelial cells, and vascular pericytes in insulin secretion and peripheral insulin action. Endocr Rev 2010;31:343–363
41. Rajala MW, Scherer PE. Minireview: the adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003;144:3765–3773
44. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010;10:328–343